Replimune Group, Inc.REPLNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank13
3Y CAGR-41.0%
5Y CAGR-35.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-41.0%/yr
vs -19.3%/yr prior
5Y CAGR
-35.6%/yr
Recent deceleration
Acceleration
-21.7pp
Decelerating
Percentile
P13
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 8.28% |
| 2024 | 38.28% |
| 2023 | 56.89% |
| 2022 | 40.27% |
| 2021 | 48.32% |
| 2020 | 74.81% |
| 2019 | 64.05% |
| 2018 | 94.87% |
| 2017 | 0.00% |